Refractory Primary Vitreoretinal Lymphoma Involving the Spinal Cord with a Temporary Complete Response to Tirabrutinib

Iizuka-Honma, Hiroko; Takizawa, Haruko; Mitsumori, Toru; Okura, Hidehiro; Ishii, Hisato; Noguchi, Masaaki

doi:10.2169/internalmedicine.9591-22

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tirabrutinib was selected as salvage treatment for this patient. Surprisingly, after two weeks, MRI showed total tumor removal and complete disappearance of the peritumoral signal abnormality ( 101 ).…”

Section: Introductionmentioning

confidence: 99%

Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review

Shen

Liu

2022

Front. Oncol.

View full text Add to dashboard Cite

Primary central nervous system lymphoma (PCNSL) is a highly aggressive brain tumor with poor prognosis if no treatment. The activation of the NF-κB (nuclear factor kappa-B) is the oncogenic hallmark of PCNSL, and it was driven by B cell receptor (BCR) and Toll-like receptor (TLR) signaling pathways. The emergence of Bruton’s tyrosine kinase inhibitors (BTKis) has brought the dawn of life to patients with PCNSL. This review summarizes the management of PCNSL with BTKis and potential molecular mechanisms of BTKi in the treatment of PCNSL. And the review will focus on the clinical applications of BTKi in the treatment of PCNSL including the efficacy and adverse events, the clinical trials currently being carried out, the underlying mechanisms of resistance to BTKi and possible solutions to drug resistance.

show abstract

Section: Introductionmentioning

confidence: 99%